【Metcela Inc.】 Metcela Resumes Clinical Trial of Regenerative Medicine Product JRM-001 to Advance Phase III Study for Pediatric Congenital Heart Disease

2025.02.26

Metcela Inc. has announced that it has submitted and received acceptance of a clinical trial protocol amendment on January 31, 2025, in order to resume the confirmatory clinical trial of JRM-001, an autologous cardiac stem cell therapy for patients with functional single ventricle.

Following a quality consultation with the Pharmaceuticals and Medical Devices Agency (PMDA), the company will proceed with the Phase III clinical trial targeting pediatric patients with congenital heart disease.

◆Clike the link below for more details
Metcela Resumes Clinical Trial of Regenerative Medicine Product JRM-001 to Advance Phase III Study for Pediatric Congenital Heart Disease